Zoetis
ZTS
71.55
+0.22
+0.31%
Zoetis
US · ZTS
#700 by market cap
Listed 1970
71.55
+0.22
+0.31%
Live - 5344 symbols - heartbeat 60s ago
· 2026-10-08 08:38
Pre-market
71.28
-0.38%
After-hours
71.55
0.00%
Overnight
71.73
+0.25%
- Market cap
- 29.57B
- P/E (TTM)i
- 11.67
- P/Bi
- 9.39
- EPSi
- 6.02
- Div yieldi
- 2.88%
- 52W posi
- 4%
Reader sentiment
Are you bullish or bearish on ZTS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 4.44, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +2.28% YoY
Margins
- Gross margin
- 71.84%
- Operating margin
- 38.00%
- Net margin
- 28.23%
Key ratios & quality
- PEG ratioi
- 1.43
- Altman Z-Scorei
- 4.44
PEG uses trailing P/E against the 3-year net income growth rate (8.13%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.83B | 6.26B | 6.68B | 7.78B | 8.08B | 8.54B | 9.26B | 9.47B |
| Gross profit | 3.91B | 4.27B | 4.62B | 5.47B | 5.63B | 5.98B | 6.54B | 6.80B |
| Selling & admin expenses | 1.48B | 1.64B | 1.73B | 2.00B | 2.01B | 2.15B | 2.32B | 2.38B |
| Research & development | 432.00M | 457.00M | 463.00M | 508.00M | 539.00M | 614.00M | 686.00M | 698.00M |
| Operating profit | 1.88B | 2.02B | 2.27B | 2.80B | 2.93B | 3.07B | 3.39B | 3.60B |
| Pretax profit | 1.69B | 1.80B | 2.00B | 2.49B | 2.66B | 2.94B | 3.13B | 3.36B |
| Tax | 266.00M | 301.00M | 360.00M | 454.00M | 545.00M | 596.00M | 637.00M | 687.00M |
| Net profit | 1.42B | 1.50B | 1.64B | 2.03B | 2.11B | 2.34B | 2.50B | 2.67B |
| Basic EPS | 3 | 3 | 3 | 4 | 5 | 5 | 5 | 6 |
| Diluted EPS | 2.93 | 3.11 | 3.42 | 4.27 | 4.49 | 5.07 | 5.47 | 6.02 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 2.20B | 2.47B | 2.40B | 2.39B | 2.26B | 2.47B |
| Gross profit | 1.58B | 1.81B | 1.72B | 1.68B | 1.62B | 1.80B |
| Selling & admin expenses | 574.00M | 614.00M | 579.00M | 619.00M | 588.00M | 592.00M |
| Research & development | 162.00M | 166.00M | 170.00M | 199.00M | 180.00M | 173.00M |
| Operating profit | 812.00M | 997.00M | 936.00M | 826.00M | 822.00M | 999.00M |
| Pretax profit | 773.00M | 912.00M | 887.00M | 761.00M | 758.00M | 866.00M |
| Tax | 171.00M | 186.00M | 166.00M | 158.00M | 157.00M | 175.00M |
| Net profit | 602.00M | 726.00M | 721.00M | 603.00M | 601.00M | 691.00M |
| Basic EPS | 1 | 2 | 2 | 1 | 1 | 2 |
| Diluted EPS | 1.34 | 1.63 | 1.63 | 1.37 | 1.42 | 1.65 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 4.40B | 4.75B | 6.61B | 6.93B | 7.51B | 6.34B | 5.99B | 6.77B |
| Cash & ST investments | 1.70B | 1.93B | 3.60B | 3.48B | 3.58B | 2.04B | 1.99B | 2.31B |
| Inventory | 1.39B | 1.41B | 1.63B | 1.92B | 2.35B | 2.56B | 2.31B | 2.43B |
| Total assets | 10.78B | 11.55B | 13.61B | 13.90B | 14.93B | 14.29B | 14.24B | 15.47B |
| Total current liabilities | 1.22B | 1.81B | 2.17B | 1.80B | 3.17B | 1.89B | 3.41B | 2.24B |
| Short-term debt | 9.00M | 500.00M | 604.00M | -- | 1.35B | 3.00M | 1.35B | -- |
| Long-term debt | 6.44B | 5.95B | 6.60B | 6.59B | 6.55B | 6.56B | 5.22B | 9.04B |
| Total liabilities | 8,592,000,000.00 | 8,837,000,000.00 | 9,836,000,000.00 | 9,356,000,000.00 | 10,522,000,000.00 | 9,295,000,000.00 | 9,467,000,000.00 | 12,136,000,000.00 |
| Total equity | 2.19B | 2.71B | 3.77B | 4.54B | 4.40B | 4.99B | 4.77B | 3.33B |
| Retained earnings | 3.27B | 4.43B | 5.66B | 7.19B | 8.67B | 10.30B | 11.97B | 13.74B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 5.88B | 5.92B | 6.58B | 6.77B | 6.47B | 6.36B |
| Cash & ST investments | 1.72B | 1.44B | 2.08B | 2.31B | 1.94B | 1.67B |
| Inventory | 2.37B | 2.44B | 2.47B | 2.43B | 2.55B | 2.57B |
| Total assets | 14.10B | 14.48B | 15.16B | 15.47B | 15.15B | 15.08B |
| Total current liabilities | 3.39B | 3.37B | 1.81B | 2.24B | 2.05B | 2.06B |
| Short-term debt | 1.35B | 1.35B | -- | -- | -- | -- |
| Long-term debt | 5.23B | 5.23B | 7.07B | 9.04B | 9.05B | 9.05B |
| Total liabilities | 9,443,000,000.00 | 9,502,000,000.00 | 9,761,000,000.00 | 12,136,000,000.00 | 11,921,000,000.00 | 11,929,000,000.00 |
| Total equity | 4.66B | 4.98B | 5.40B | 3.33B | 3.23B | 3.15B |
| Retained earnings | 12.38B | 12.87B | 13.59B | 13.74B | 14.18B | 14.65B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1.79B | 1.80B | 2.13B | 2.21B | 1.91B | 2.35B | 2.95B | 2.90B |
| Depreciation & amortization | 308.00M | 412.00M | 441.00M | 448.00M | 465.00M | 491.00M | 497.00M | 487.00M |
| Free cash flow | 1.45B | 1.34B | 1.67B | 1.74B | 1.33B | 1.62B | 2.30B | 2.28B |
| Dividends paid | -243.00M | -314.00M | -380.00M | -474.00M | -611.00M | -692.00M | -786.00M | -889.00M |
| Stock buybacks / issuance | -698.00M | -626.00M | -250.00M | -743.00M | -1.59B | -1.09B | -1.86B | -3.24B |
| Ending cash balance | 1.60B | 1.93B | 3.60B | 3.49B | 3.58B | 2.04B | 1.99B | 2.31B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 515.00M | 605.00M | 891.00M | 893.00M | 401.00M | 655.00M |
| Depreciation & amortization | 119.00M | 124.00M | 123.00M | 121.00M | 119.00M | 119.00M |
| Free cash flow | 337.00M | 459.00M | 755.00M | 732.00M | 291.00M | 538.00M |
| Dividends paid | -224.00M | -223.00M | -222.00M | -220.00M | -224.00M | -223.00M |
| Stock buybacks / issuance | -443.00M | -338.00M | -394.00M | -2.06B | -606.00M | -584.00M |
| Ending cash balance | 1.78B | 1.63B | 2.08B | 2.31B | 1.94B | 1.48B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 72.21 | 61.31 | 50.58 | 49.01 | 47.25 | 49.86 | 50.91 | 65.99 |
| ROA %i | 14.75 | 13.44 | 13.02 | 14.81 | 14.67 | 16.05 | 17.43 | 18.00 |
| ROIC %i | 20.50 | 18.43 | 17.78 | 20.31 | 17.90 | 20.22 | 22.19 | 24.42 |
| 5-year avg ROE %i | 53.97 | 55.87 | 60.28 | 57.23 | 56.07 | 51.60 | 49.52 | 52.60 |
| EBIT margin %i | 32.55 | 32.33 | 33.36 | 34.88 | 35.61 | 37.16 | 36.28 | 37.84 |
| FCF / sales %i | 24.93 | 21.33 | 25.06 | 22.33 | 16.41 | 18.97 | 24.83 | 24.12 |
| Current ratioi | 3.60 | 2.63 | 3.05 | 3.86 | 2.37 | 3.36 | 1.75 | 3.03 |
| Quick ratioi | 2.23 | 1.67 | 2.13 | 2.57 | 1.51 | 1.77 | 0.97 | 1.74 |
| Debt / assetsi | 59.87 | 57.26 | 54.10 | 48.51 | 54.20 | 47.28 | 47.37 | 59.73 |
| LT debt / equityi | 294.87 | 225.66 | 179.30 | 148.43 | 152.96 | 135.12 | 113.08 | 277.33 |
| Interest coveragei | 9.20 | 9.08 | 9.64 | 12.11 | 13.02 | 13.28 | 14.92 | 16.14 |
| Revenue CAGR (3Y) %i | 6.92 | 8.60 | 7.94 | 10.11 | 8.88 | 8.58 | 5.98 | 5.42 |
| Net income CAGR (3Y) %i | 61.50 | 22.25 | 23.77 | 12.57 | 12.12 | 12.69 | 6.87 | 8.13 |
| FCF CAGR (3Y) %i | 48.88 | 39.01 | 14.24 | 6.14 | -0.23 | -1.05 | 9.80 | 19.85 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 51.85 | 52.54 | 49.87 | 65.99 | 67.75 | 64.91 |
| ROA %i | 17.70 | 18.24 | 17.96 | 18.00 | 18.27 | 17.84 |
| ROIC %i | 22.52 | 21.82 | 22.28 | 24.42 | 24.70 | 24.18 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 36.80 | 37.65 | 37.75 | 37.84 | 37.51 | 37.13 |
| FCF / sales %i | 24.56 | 23.64 | 23.84 | 24.12 | 23.47 | 24.32 |
| Current ratioi | 1.74 | 1.76 | 3.64 | 3.03 | 3.15 | 3.08 |
| Quick ratioi | 0.91 | 0.88 | 2.00 | 1.74 | 1.68 | 1.57 |
| Debt / assetsi | 47.88 | 46.90 | 47.98 | 59.73 | 60.96 | 61.27 |
| LT debt / equityi | 116.00 | 109.32 | 134.74 | 277.33 | 285.74 | 293.46 |
| Interest coveragei | 15.46 | 16.43 | 16.42 | 16.14 | 15.54 | 14.86 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Parasiticides is the largest reported line at 28.28% of revenue, across 9 reported segments.
- No single line clears half of revenue; Vaccines is next at 21.11%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Parasiticides28.28%
Vaccines21.11%
Dermatology16.13%
Anti-infectives9.89%
Pain and sedation8.79%
Other pharmaceuticals6.81%
Animal health diagnostics4.98%
Other non-pharmaceuticals2.84%
Contract manufacturing & human health1.18%
Quote time 2026-10-08 08:38:57 · For reference only, not investment advice and not tailored to your situation.